Survey on vaccine data looks to improve ways pharmacy can share information

Survey on vaccine data looks to improve ways pharmacy can share information

May 17 2018 The Professional Record Standards Body (PRSB) is inviting views on information...

Psoriasis Assocation launches WhatsApp service

Psoriasis Assocation launches WhatsApp service

May 15 2018 A new support service for people with psoriasis has been launched by Psoriasis...

NHS to introduce new measures to help monitor medication errors

NHS to introduce new measures to help monitor medication errors

May 15 2018 The NHS is to introduce a series of new indicators to show whether a prescription may...

ICO consults on how it should use its increased regulatory powers with GDPR

ICO consults on how it should use its increased regulatory powers with GDPR

May 11 2018 The Information Commissioner’s Office is asking for views on the way it intends...

RCGP offers advice for around online consultations safety

RCGP offers advice for around online consultations safety

April 11 2018 Advice and considerations around the safety of online patient consultations has...

  • Survey on vaccine data looks to improve ways pharmacy can share information

    Survey on vaccine data looks to improve ways pharmacy can share information

    Thursday, 17 May 2018 15:26
  • Psoriasis Assocation launches WhatsApp service

    Psoriasis Assocation launches WhatsApp service

    Tuesday, 15 May 2018 12:10
  • NHS to introduce new measures to help monitor medication errors

    NHS to introduce new measures to help monitor medication errors

    Tuesday, 15 May 2018 11:58
  • ICO consults on how it should use its increased regulatory powers with GDPR

    ICO consults on how it should use its increased regulatory powers with GDPR

    Friday, 11 May 2018 11:38
  • RCGP offers advice for around online consultations safety

    RCGP offers advice for around online consultations safety

    Wednesday, 11 April 2018 13:19

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Management News

May 23 2018 Over 2,000 patients were removed from GP lists due to allegations of violence or threats in 2017. A further 10,000 were removed due to a break down in the relationship between the GP and...
May 18 2018 New guidance to support the integration of community pharmacy services into primary care homes (PCHs) has been published.  The National Association of Primary Care’s report looks at ways...